Cargando…
Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
Vasopressin V2 receptor (V2R) antagonists (vaptans) are a new generation of diuretics. Compared with classical diuretics, vaptans promote the excretion of retained body water in disorders in which plasma vasopressin concentrations are inappropriately high for any given plasma osmolality. Under these...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981680/ https://www.ncbi.nlm.nih.gov/pubmed/31888044 http://dx.doi.org/10.3390/ijms21010183 |
_version_ | 1783491137683587072 |
---|---|
author | Di Mise, Annarita Venneri, Maria Ranieri, Marianna Centrone, Mariangela Pellegrini, Lorenzo Tamma, Grazia Valenti, Giovanna |
author_facet | Di Mise, Annarita Venneri, Maria Ranieri, Marianna Centrone, Mariangela Pellegrini, Lorenzo Tamma, Grazia Valenti, Giovanna |
author_sort | Di Mise, Annarita |
collection | PubMed |
description | Vasopressin V2 receptor (V2R) antagonists (vaptans) are a new generation of diuretics. Compared with classical diuretics, vaptans promote the excretion of retained body water in disorders in which plasma vasopressin concentrations are inappropriately high for any given plasma osmolality. Under these conditions, an aquaretic drug would be preferable over a conventional diuretic. The clinical efficacy of vaptans is in principle due to impaired vasopressin-regulated water reabsorption via the water channel aquaporin-2 (AQP2). Here, the effect of lixivaptan—a novel selective V2R antagonist—on the vasopressin-cAMP/PKA signaling cascade was investigated in mouse renal collecting duct cells expressing AQP2 (MCD4) and the human V2R. Compared to tolvaptan—a selective V2R antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia—lixivaptan has been predicted to be less likely to cause liver injury. In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256. Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increase in osmotic water permeability. These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention. |
format | Online Article Text |
id | pubmed-6981680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69816802020-02-07 Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells Di Mise, Annarita Venneri, Maria Ranieri, Marianna Centrone, Mariangela Pellegrini, Lorenzo Tamma, Grazia Valenti, Giovanna Int J Mol Sci Article Vasopressin V2 receptor (V2R) antagonists (vaptans) are a new generation of diuretics. Compared with classical diuretics, vaptans promote the excretion of retained body water in disorders in which plasma vasopressin concentrations are inappropriately high for any given plasma osmolality. Under these conditions, an aquaretic drug would be preferable over a conventional diuretic. The clinical efficacy of vaptans is in principle due to impaired vasopressin-regulated water reabsorption via the water channel aquaporin-2 (AQP2). Here, the effect of lixivaptan—a novel selective V2R antagonist—on the vasopressin-cAMP/PKA signaling cascade was investigated in mouse renal collecting duct cells expressing AQP2 (MCD4) and the human V2R. Compared to tolvaptan—a selective V2R antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia—lixivaptan has been predicted to be less likely to cause liver injury. In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256. Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increase in osmotic water permeability. These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention. MDPI 2019-12-26 /pmc/articles/PMC6981680/ /pubmed/31888044 http://dx.doi.org/10.3390/ijms21010183 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Di Mise, Annarita Venneri, Maria Ranieri, Marianna Centrone, Mariangela Pellegrini, Lorenzo Tamma, Grazia Valenti, Giovanna Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells |
title | Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells |
title_full | Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells |
title_fullStr | Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells |
title_full_unstemmed | Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells |
title_short | Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells |
title_sort | lixivaptan, a new generation diuretic, counteracts vasopressin-induced aquaporin-2 trafficking and function in renal collecting duct cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981680/ https://www.ncbi.nlm.nih.gov/pubmed/31888044 http://dx.doi.org/10.3390/ijms21010183 |
work_keys_str_mv | AT dimiseannarita lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells AT vennerimaria lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells AT ranierimarianna lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells AT centronemariangela lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells AT pellegrinilorenzo lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells AT tammagrazia lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells AT valentigiovanna lixivaptananewgenerationdiureticcounteractsvasopressininducedaquaporin2traffickingandfunctioninrenalcollectingductcells |